Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02088866 · ClinicalTrials.gov registry record · Early Phase 1
Commercial Lidocaine Patch as a Treatment for Ear-ringing
A Early Phase 1 study, sponsored by University of California, Davis.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
NCT02088866: Completed Early Phase 1 study, sponsored by University of California, Davis.
NCT02088866 is a Early Phase 1 study that has completed, run by University of California, Davis. The registered enrollment target is 30 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (43% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02088866, a Early Phase 1 study, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this investigation is to evaluate if topically applied lidocaine, in the form of lidocaine patches, reduces the burden of chronic subjective tinnitus in a consistent and measurable way.
Primary Outcome
The primary study endpoint is change in tinnitus tolerance based on the tinnitus functional index. TFI will be measured at initial appointment and will be measured again at 4±1 weeks for any change in outcome, then again at 8±1 weeks for any subsequent change to outcome, and finally at 12±1 weeks follow-up for any subsequent change to outcome, up to a maximum time frame of 12 weeks from date of enrollment.
Interventions
- DRUG Transdermal Lidocaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2014-03 |
| Est. Completion | 2015-09 |
| Phase | Early Phase 1 |
What the finished NCT02088866 record still lists
NCT02088866 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (43% lower).
The record links to 0 conditions, and to 1 intervention - of which Transdermal Lidocaine is the first listed.
NCT02088866 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02088866 about?
NCT02088866 is a clinical study titled "Commercial Lidocaine Patch as a Treatment for Ear-ringing". The purpose of this investigation is to evaluate if topically applied lidocaine, in the form of lidocaine patches, reduces the burden of chronic subjective tinnitus in a consistent and measurable way.
What is the current status of trial NCT02088866?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2014-03. Estimated completion is 2015-09.
What interventions are being tested in trial NCT02088866?
The interventions under investigation include: Transdermal Lidocaine (DRUG).
Who is sponsoring clinical trial NCT02088866?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02088866's enrollment target sits among peer trials
30 807th of 2000 higher than 1,074 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia